Table 3.
Clinicopathological Characteristics among EBVaGCs and EBVnGCs According to the Expression of PD-L1 and STING
| Characteristics | PD-L1 | STING | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBVaGC | EBVnGC | EBVaGC | EBVnGC | ||||||||||||
| Positive (n=49) | Negative (n=27) | p-value | Positive (n=35) | Negative (n=175) | p-value | Positive (n=48) | Negative (n=28) | p-value | Positive (n=104) | Negative (n=106) | p-value | ||||
| Age, yr | |||||||||||||||
| Mean±SD | 59.2±10.0 | 62.6±11.6 | 0.182 | 60.3±12.4 | 62.5±10.5 | 0.294 | 61.0±10.1 | 59.5±11.7 | 0.569 | 62.5±10.9 | 61.7±10.8 | 0.633 | |||
| <60 | 20 (40.8) | 9 (33.3) | 0.520 | 13 (37.1) | 65 (37.1) | 1.000 | 17 (35.4) | 12 (42.9) | 0.502 | 37 (35.6) | 41 (38.7) | 0.642 | |||
| ≥60 | 29 (59.2) | 18 (66.7) | 22 (62.9) | 110 (62.9) | 31 (64.6) | 16 (57.1) | 67 (64.4) | 65 (61.3) | |||||||
| Gender | |||||||||||||||
| Male | 42 (85.7) | 24 (88.9) | 0.970 | 27 (77.1) | 122 (69.7) | 0.377 | 43 (89.6) | 23 (82.1) | 0.355 | 74 (71.2) | 75 (70.8) | 0.949 | |||
| Female | 7 (14.3) | 3 (11.1) | 8 (22.9) | 53 (30.3) | 5 (10.4) | 5 (17.9) | 30 (28.8) | 31 (29.2) | |||||||
| Location | |||||||||||||||
| Proximal | 38 (77.6) | 21 (77.8) | 0.982 | 22 (62.9) | 115 (65.7) | 0.746 | 35 (72.9) | 24 (85.7) | 0.314 | 70 (67.3) | 64 (60.4) | 0.296 | |||
| Distal | 11 (22.4) | 6 (22.2) | 13 (37.1) | 60 (34.3) | 13 (27.1) | 4 (14.3) | 34 (32.7) | 42 (39.6) | |||||||
| Tumor size, cm | |||||||||||||||
| Mean±SD | 4.9±2.6 | 4.2±2.4 | 0.249 | 5.4±2.4 | 4.7±2.4 | 0.122 | 5.0±2.5 | 4.1±2.4 | 0.098 | 4.8±2.3 | 4.8±2.5 | 0.970 | |||
| <5 | 29 (59.2) | 16 (59.3) | 0.995 | 16 (45.7) | 100 (57.1) | 0.215 | 27 (56.3) | 18 (64.3) | 0.492 | 55 (52.9) | 61 (57.5) | 0.497 | |||
| ≥5 | 20 (40.8) | 11 (40.7) | 19 (54.3) | 75 (42.9) | 21 (43.7) | 10 (35.7) | 49 (47.1) | 45 (42.5) | |||||||
| Differentiation | |||||||||||||||
| Well/moderate | 15 (30.6) | 7 (25.9) | 0.666 | 14 (40.0) | 99 (56.6) | <0.001* | 15 (31.3) | 7 (25.0) | 0.562 | 58 (55.8) | 55 (51.9) | 0.573 | |||
| Poor | 34 (69.4) | 20 (74.1) | 21 (60.0) | 76 (43.4) | 33 (68.7) | 21 (75.0) | 46 (44.2) | 51 (48.1) | |||||||
| Lauren’s type | |||||||||||||||
| Intestinal | 29 (59.2) | 8 (29.6) | 0.014* | 11 (31.4) | 112 (64.0) | <0.001* | 27 (56.3) | 10 (35.7) | 0.084 | 57 (54.8) | 66 (62.3) | 0.273 | |||
| Diffuse/mixed | 20 (40.8) | 19 (70.4) | 24 (68.6) | 63 (36.0) | 21 (43.7) | 18 (64.3) | 47 (45.2) | 40 (37.7) | |||||||
| LVI | |||||||||||||||
| Absent | 36 (73.5) | 14 (51.9) | 0.057 | 14 (40.0) | 66 (37.7) | 0.799 | 36 (75.0) | 14 (50.0) | 0.027* | 37 (35.6) | 43 (40.6) | 0.457 | |||
| Present | 13 (26.5) | 13 (48.1) | 21 (60.0) | 109 (62.3) | 12 (25.0) | 14 (50.0) | 67 (64.4) | 63 (59.4) | |||||||
| PI | |||||||||||||||
| Absent | 19 (38.8) | 6 (22.2) | 0.142 | 10 (28.6) | 44 (25.1) | 0.672 | 19 (39.6) | 6 (21.4) | 0.104 | 24 (23.1) | 30 (28.3) | 0.386 | |||
| Present | 30 (61.2) | 21 (77.8) | 25 (71.4) | 131 (74.9) | 29 (60.4) | 22 (78.6) | 80 (76.9) | 76 (71.7) | |||||||
| pTumor depth | |||||||||||||||
| pT1/2 | 21 (42.9) | 9 (33.3) | 0.416 | 6 (17.1) | 39 (22.3) | 0.498 | 18 (37.5) | 12 (42.9) | 0.645 | 20 (19.2) | 25 (23.6) | 0.442 | |||
| pT3/4 | 28 (57.1) | 18 (66.7) | 29 (82.9) | 136 (77.7) | 30 (62.5) | 16 (57.1) | 84 (80.8) | 81 (76.4) | |||||||
| pLNM | |||||||||||||||
| Absent | 27 (55.1) | 10 (37.1) | 0.132 | 5 (14.3) | 35 (20.0) | 0.432 | 26 (54.2) | 11 (39.3) | 0.211 | 18 (17.3) | 84 (79.2) | <0.001* | |||
| Present | 22 (44.9) | 17 (62.9) | 30 (85.7) | 140 (80.0) | 22 (45.8) | 17 (60.7) | 86 (82.7) | 22 (20.8) | |||||||
| pTNM | |||||||||||||||
| I/II | 32 (65.3) | 14 (51.9) | 0.251 | 10 (28.6) | 63 (36.0) | 0.400 | 30 (62.5) | 16 (57.1) | 0.645 | 34 (32.7) | 39 (36.8) | 0.533 | |||
| III/IV | 17 (34.7) | 13 (48.1) | 25 (71.4) | 112 (64.0) | 18 (37.5) | 12 (42.9) | 70 (67.3) | 67 (63.2) | |||||||
| Histologic subtypes | |||||||||||||||
| LELC | 24 (49.0)† | 5 (18.6) | 0.013* | NA | NA | 22 (45.8) | 7 (25.0) | 0.188 | NA | NA | |||||
| CLR | 17 (34.7) | 11 (40.7) | 15 (31.3) | 13 (46.4) | |||||||||||
| CA | 8 (16.3)‡ | 11 (40.7) | 11 (22.9)§ | 8 (28.6) | |||||||||||
Data are presented as number (%) unless otherwise indicated.
EBV, Epstein-Barr virus; GC, gastric cancer; EBVaGC, EBV-associated GC; EBVnGC, EBV-negative GC; PD-L1, programmed death-ligand 1; STING, stimulator of interferon genes; LVI, lymphatic vascular invasion; PI, perineural invasion; LNM, lymph node metastasis; LELC, lymphoepithelioma-like carcinoma; CLR, adenocarcinoma with Crohn’s disease-like lymphocytic reaction; CA, conventional adenocarcinoma; NA, not available.
*Statistically significant, p<0.05; †p=0.003 vs CA, ‡p=0.019 vs LELC+CLR, §p=0.583 vs LELC+CLR.